Department of Chemotherapy, Affiliated Cancer Hospital of GuangXi Medical University, Nanning, China.
Leuk Lymphoma. 2013 Jul;54(7):1418-25. doi: 10.3109/10428194.2012.748907. Epub 2012 Dec 7.
The prognostic significance of angiogenic markers remains controversial. Many studies have suggested that vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) overexpression correlates with poorer survival in adult patients with acute myeloid leukemia (AML), but some studies suggest a greater probability of survival. To investigate the prognostic significance of VEGF overexpression in adult AML, we performed a meta-analysis of the published studies that provided survival information according to VEGF expression status. Pooled hazard ratios (HRs) indicated that VEGF overexpression had a poor impact on the survival of adult patients with AML. The combined hazard ratio for event-free survival (EFS) was 1.40 and summary HR for overall survival was 1.54. The pooled HR was 1.92 in AML by enzyme-linked immunosorbent assay and 1.67 in AML by immunohistochemistry. These findings indicate that VEGF overexpression has an adverse impact on prognosis for patients with AML. VEGF may become a useful prognostic factor in the context of targeted therapy for patients with adult AML.
血管生成标志物的预后意义仍存在争议。许多研究表明，血管内皮生长因子（VEGF）或血管内皮生长因子受体（VEGFR）的过度表达与成人急性髓系白血病（AML）患者的生存率较差相关，但也有一些研究表明其具有更高的生存概率。为了探究 VEGF 过表达在成人 AML 中的预后意义，我们对提供了根据 VEGF 表达状态的生存信息的已发表研究进行了荟萃分析。合并风险比（HRs）表明，VEGF 过表达对 AML 成年患者的生存有不良影响。无事件生存（EFS）的合并风险比为 1.40，总生存的汇总 HR 为 1.54。酶联免疫吸附试验检测到的 AML 的合并 HR 为 1.92，免疫组织化学检测到的 AML 的合并 HR 为 1.67。这些发现表明，VEGF 过表达对 AML 患者的预后有不良影响。VEGF 可能成为针对成人 AML 患者的靶向治疗的有用预后因素。
